BCPA
CAS No. 547731-67-9
BCPA( —— )
Catalog No. M36956 CAS No. 547731-67-9
BCPA is a non-cytotoxic Pin1 modulator.BCPA modulates osteoclast activation and attenuates the reduction of Pin1 protein, thereby inhibiting RANKL-induced receptor activators of osteoclastogenesis.BCPA is used in the study of osteoporosis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 32 | In Stock |
|
| 10MG | 51 | In Stock |
|
| 25MG | 110 | In Stock |
|
| 50MG | 173 | In Stock |
|
| 100MG | 277 | In Stock |
|
| 200MG | 390 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBCPA
-
NoteResearch use only, not for human use.
-
Brief DescriptionBCPA is a non-cytotoxic Pin1 modulator.BCPA modulates osteoclast activation and attenuates the reduction of Pin1 protein, thereby inhibiting RANKL-induced receptor activators of osteoclastogenesis.BCPA is used in the study of osteoporosis.
-
DescriptionBCPA is a Pin1 regulator without cytotoxicity. BCPA attenuates the reduction of Pin1 protein to inhibit receptor activator of RANKL-induced osteoclastogenesis. BCPA regulates osteoclast activation, used to osteoporosis research.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number547731-67-9
-
Formula Weight417.33
-
Molecular FormulaC22H22Cl2N2O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 6.67 mg/mL (15.98 mM; Ultrasonic (<80°C)
-
SMILESC(=CC(NCCCCNC(C=CC1=C(Cl)C=CC=C1)=O)=O)C2=C(Cl)C=CC=C2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Vipivotide tetraxeta...
Vipivotide tetraxetan is a high potent inhibitor of prostate-specific membrane antigen (PSMA)(Ki of 0.37 nM).
-
2-(2,6-dioxopiperidi...
2-(2,6-dioxopiperidin-3-yl)-4-((7-hydrox is protac.
-
24-Norursodeoxycholi...
24-norursodeoxycholic acid is a side chain-shortened C23 homolog of UDCA.It has shown potent anti-inflammatory, anti-cholestatic, and anti-fibrotic properties.It is a Ursodeoxycholic Acid derivative. It is superior to Ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice24-norUrsodeoxycholic acid markedly improved liver tests and liver histology and significantly reduced hydroxyproline content and the number of infiltrating neutrophils and proliferating hepatocytes and cholangiocytes.?
Cart
sales@molnova.com